fosamax vs evista
Click on image below to visit fosamax Online Page
Business Editors/Health/Medical Writers
WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Aug. 28, 2003
Merck & Co., Inc. announced today that the U.S. District Court in Wilmington, Del., upheld Merck’s U.S. patent covering the weekly administration of FOSAMAX(R) (alendronate sodium) Once-Weekly. As a result of the court’s decision, the patent is valid and infringed by Teva Pharmaceuticals USA, Inc.’s Abbreviated New Drug Application (ANDA) filing. Merck filed a patent infringement lawsuit against Teva in January 2001. The FOSAMAX Once-Weekly patent expires in July 2018. The court’s decision is subject to appeal.
FOSAMAX is the world’s leading non-hormonal medicine for the treatment of osteoporosis.
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures.
Forward-Looking Statements
Advertisement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and product potential. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the company’s businesses, particularly those mentioned in the caVitamin d and fosamax
Fosamax joint pain
Fosamax adverse effects
Fosamax research
Fosamax and evista
alendronate fosamax sodium
Studies done in germany on fosamax
July 4th, 2008 at 6:17 am
[…] Fosamax, like other bisphosphonates, should be used with caution in people with certain stomach or digestive problems. Fosamax should not be used if the patient has certain disorders of the esophagus that delay emptying or if the patient is unable to stand or sit upright for at least 30 minutes. In addition, Fosamax should not be used in patients with severe kidney disease or low levels of calcium in their blood, in patients who are allergic to Fosamax or in patients who are pregnant or nursing. […]